Value What Matters!
The value specialist for innovative Life Sciences and High Growth / High Risk ventures
Context, details and numbers shaping decision making in environments where alignment and success demand exceptional diligence.
At the intersection of science, finance and the psychology of risk
In innovative Life Sciences and High Growth / High Risk, value is not a given. It emerges from decisions — to invest, to partner, to fund, to exit — often when assets are incomplete, uncertain or contested. We operate at this friction point. Aligning scientific potential, financial reality and stakeholder motivation.
We see value before it is fully visible.
And we understand how investment decisions are actually made.
We help innovative Life Sciences and High Growth / High Risk decision-makers act with clarity where outcomes are not yet visible and timing matters.
Decision contexts are central
Value in innovative Life Sciences and High Growth / High Risk is event-driven. It moves through transitions — moments where it is tested, reframed, or redefined.
From investment and structuring to partnering, continuous negotiation and critical reporting, investors, management, and boards operate within a deliberate, context-specific process that places human judgment at its core.
Each transition brings its own dynamics, strongly influenced by business maturity (including understanding of the science, its potential, and market adoption characteristics), investor profile, board composition, and the management team’s seniority within its financing ecosystem—meaning value realization goes beyond the narrow concept of asset value.
This is why we structure our work around business maturity, decision and reporting contexts.
Clarity ahead for Decision Makers
Get to the true value and what drives it. Manage optionality ahead, as capital expects.
Early investment readiness
For incubators and young companies. Shape the path from science to capital.
You may be surprised by the importance we give to context—and to the investor’s perspective.
High Growth / High Risk is about managing what is uncertain. It requires alignment.
The Fair Value specialist who understands value reality.
Valuation is often said to sit between science and art. Everyone nods, yet the poetry hides the point: clarity is missing on what matters, why, and therefore, how it should be valued.
What sits between science and art is alignment — between stakeholders, under uncertainty.
That´s why two distinct contexts for Fair Value prevail, each with its own playbook :
- When what is to be valued and why it matters is established upfront and governed by official guidelines. Whether for accounting, legal, tax or some governance purposes, the first step is mastering the rules. Most trace back to ASC 820-10 (US) and IFRS 13 (international). But mastery goes beyond compliance. High Growth/High Risk innovative ventures operate in levels of uncertainty that demands a trained eye to isolate what truly drives value and advanced computational methods capable of making sense of the unknown.
- When what matters truly emerges through negotiation, arbitrage, or ruling. The final agreed terms reveal which value drivers ultimately prevailed. Here, fair is not inherent, it is achieved. Each side brings its own logic, incentives, and priorities. Success demands a trained eye to read complex dynamics and behaviors, to route to optimum.
Sophisticated valuation methods? They are our terrain.
Ralph Villiger is a pioneer and thought leader in innovative Life Sciences valuation. He authored arguably the field´s most widely recognized foundational book, published numerous papers, trained hundreds of executives and launched an early-stage VC fund.
From fairness opinion to transactional matters, we know not only which advanced methods to deploy, but how to calibrate them so they adequately capture what matters.
Risk-adjusted Net Present Value (rNPV), Monte Carlo simulations (MC), Option Pricing Models (OPM), Real Options, Probability-Weighted Expected Return Method (PWERM), or retro-engineering of comparators are all standard tools in our practice.
We also recognize when a valuation is unnecessary—a fiction that does not advance fair outcomes.
Transactions are our everyday.
Fundraising, IPOs, licensing deals, trade sales, partial and full exits define the journey of innovative Life Sciences and High Growth/High Risk ventures.
Excellence here demands more than knowledge: it requires embedded expertise, longitudinal collaboration with management and investors, and deep strategic intelligence in the field. This insight informs decisions, mitigates risk, and elevates every key transaction moment.
Ultimately, valuation means probing the intimacy of a business—whether guided by formal rules or specific objectives. True insight always comes from context: the forces at play, the intentions behind the numbers, and the human dynamics that make all the difference.
Meet you where you are: in sync with innovative ventures and investors
Innovative Life Sciences and High Growth/High Risk ventures follow a distinctive risk/reward pattern, yet every journey is unique. From initial deals to long term strategy, management and investors alike face uncertainy, steep decisions, shifting dynamics, and constant adjustment.
We step in exactly when and how it matters, bringing insight, precision, discipline, and the agility to act and adapt as circumstances unfold.
Handle urgency like a reflex
"When do you need it?" "…for yesterday?" It happens more often than not. And we don’t flinch.
In the world of High Growth / High Risk and Life Sciences innovation, urgency is not the exception, it’s the rule. Patent and IRR clocks tick, deal-momentum can vanish quickly and an unwise trade-off can derail the whole.
When timing matters most, we don’t just move fast. We turn urgency into precision, identify what truly matters, and outsmart situations—keeping you ahead, with confidence.
Building value that holds
In innovative High Growth / High Risk and Life Sciences, from the spark of an idea to the market, the journey is a continuous transformation for the asset, the team and the capital structure.
Underlying drivers can either support or constrain how value emerges and evolves. Progress is not only about advancing — it is about strengthening the drivers that enable trajectory, and moving beyond those that limit it.
Readiness. Value reality.
Rising to the next inflection point requires operating at a higher level. This isn’t automatic, it is achieved.
Beyond valuation, we bring a structured view of these dynamics.
The outside view that moves things forward
Innovative, patent-protected High Growth/High Risk and Life Sciences ventures operate under tight constraints — cash, talent, and time. They are sharp and nimble.
We bring a perspective that is both detached and deeply embedded: an impartial +1 that reads the room, understands your context, and steps into exactly the role that’s needed — no more, no less.
We mirror your stage of readiness and the perspectives of your key stakeholders. We surface insights that can be hard to hear, yet always fair. You gain time, clarity, and control. This is support that truly moves things forward.